Your search for bevacizumab returned 19 results

Alymsys is a vascular endothelial growth factor inhibitor.

There was no improvement in overall survival with bevacizumab.

The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.

Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first

Vegzelma is a vascular endothelial growth factor inhibitor.

At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.

The approval was based on data from the phase 3 KEYNOTE-826 trial.